Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Review of hedge fund launches, closures, trends, regulatory and legal events - week 33

Saturday, August 20, 2011

Asian hedge funds led the launch news last week as we learned multiple commodities trading advisors (CTA) and systematic trading hedge funds are in the pipeline in Asia. Schroder Investment Management is considering launching a global version of its Asian high-yield multi-asset fund. QS Investors LLC announced a plan to launch a $1bn Liquid Alpha Fund inflation hedge fund (UCITS). And former Butterfield Fulcrum CEO Akshaya Bhargava launched a managed account platform.

In assets: Despite the market turbulence, investors are largely standing by their hedge fund investments. BlackRock aims to double its allocation to hedge funds and private equity.

Hedge funds reported their 2Q performances led by New York-based Kerrisdale Partners LP, which was up +44.8% in 2Q (+150.8 YTD) shorting Chinese companies in the U.S. The 'Twitter' hedge fund Derwent Capital Markets proved social media can predict the markets as it returned 1.57% on its first month. Global macro hedge fund Callanish was up +1.5% YTD on capital protection through risk management. MQS Automated Multi-System CTA Program was up +2.26% in July (+12.01% YTD).

Crispin Odey’, the co-founder of Odey Asset Management said his flagship European fund fell 5.3% in July as investors became “scared of the unknown.” Tlaloc Capital gains +11.68% YTD, bet short on corn.

The RBC Hedge 250 Index returned +0.29%in July (+0.93%YTD); the Barclay Hedge Fund Index almost flat with -0.01% (+1.06% YTD); ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for